Treatment of elderly patients with acute lymphoblastic leukemia - Evidence for a benefit of imatinib in BCR-ABL positive patients

Leukemia Research

Volumn 29, Issue 12, 2005, Pages 1381-1386

  Brandwein, J M ^a   Gupta, V ^a   Wells, R A ^a   Schuh, A C ^a   Schimmer, A D ^a   Lipton, J H ^a   Messner, H A ^a   Yi, Q L ^b   Chun, K ^c   Kamel Reid, S ^c   Minden, M D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute lymphoblastic leukaemia; BCR ABL; Chemotherapy; Imatinib

Indexed keywords

BCR ABL PROTEIN; IMATINIB; LACTATE DEHYDROGENASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; EVALUATION; FEMALE; HOSPITALIZATION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 27644470269     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.04.020     Document Type: Article

References (20)

1. P.R.A. Taylor, M.M. Reid, N. Brown, P.J. Hamilton, and S.J. Proctor Acute lymphoblastic leukemia in patients aged 60 years and over: a population based study of incidence and outcome Blood 80 1992 1813 1817
2. G.F. Laport, and R.A. Larson Treatment of adult acute lymphoblastic leukemia Semin Oncol 24 1997 70 82
3. M. Hunault, J.L. Harousseau, and M. Delain Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial Blood 104 2004 3028 3037
4. V. Gupta, Q.-L. Yi, and J. Brandwein The role of genoidentical allogeneic bone marrow transplantation in adult patient below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor versus no donor comparison Bone Marrow Transplant 33 2004 397 404
5. L. Pagano, L. Mele, Trape, and G. Leone The treatment of acute lymphoblastic leukemia in the elderly Leuk Lymph 45 2004 117 123
6. F. Mandelli, L. Annino, and M.L. Vegna Treatment of acute lymphoblastic leukemia in the elderly: result of the GIMEMA ALL 0288 >60 years trial Buchner Acute leukemias VI. Prognostic factors and treatment strategies 1997 688 694
7. X. Thomas, N. Olteanu, and C. Charrin Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience Am J Hematol 67 2002 73 83
8. H.M. Kantarjian, S. O'Brien, and S. Smith Acute lymphocytic leukemia in the elderly: characteristics and outcome with the vincristine-adriamycin- dexamethasone (VAD) regimen Br J Haematol 88 1994 94 100
9. L.B. Silverman, R.D. Gelber, and V.K. Dalton Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 Blood 97 2001 1211 1218
10. D.A. Thomas, J. Cortes, and S. O'Brien Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia J Clin Oncol 17 1999 2461 2470
11. K. Stewart, A. Keating, and D. Sutton Adult acute lymphoblastic leukemia: the value of early intensification Leuk Lymph 4 1991 103 110
12. E. Matutes, R. Morilla, and N. Faraht Definition of acute biphenotypic leukemia Haematologica 82 1997 64 66
13. Rosner B, Fundamentals of biostatistics. 4th ed. US: Wadsworth Publishing Company; 1995. p. 607-28.
14. SAS/STAT user's guide, version 8, Cary, NC: SAS Institute Inc.; 1999.
15. D.A. Thomas, S. Faderl, and J. Cortes Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 103 2004 4396 4407
16. M. Towatari, M. Yanada, and N. Usui Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood 104 2004 3507 3512
17. O.G. Ottmann, B. Wassman, and N. Goekbuget A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia Blood 102 2003 226a
18. C.L. Sawyers, N.P. Shah, and H.M. Kantarjian Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a Phase I dose escalation study Blood 104 2004 4a
19. V. Gupta, K. Chun, and Q-L. Yi Disease biology rather than age is the most important predictor of survival in AML patients >60 years treated with uniform intensive therapy Cancer 103 2005 2082 2090
20. F. Giles, H. Kantarjian, and B. Wassmann A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, on a continuous daily dosing schedule in adult patients with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) Blood 104 2004 10a